CYP19A1 and endometrial cancer: These results have demonstrated a clearly benefit of aromatase inhibitors, compared with tamoxifen, as adjuvant treatment for breast carcinoma, and also a better sequrity profile, since a significant reduction in hot flushes, vaginal discharge, vaginal bleeding, ishcemic cerebrovascular events, and endometrial cancer has been informed.